Alembic Pharma successfully completes USFDA inspection for Panelav facility
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-07-26 08:00 GMT | Update On 2024-07-26 08:00 GMT
Advertisement
Vadodara: Alembic Pharma has announced that the Company has successfully completed the United States Food and Drug Administration (USFDA) inspection for its Oral Solid Formulation Facility (F-I) located at Panelav.
This was a scheduled GMP inspection and was successfully completed without any Form 483 observation.
The inspection was conducted from 17th July, 2024 to 26th July, 2024.
Medical Dialogues team had earlier reported that the Company had received an Establishment Inspection Report (EIR) from the US FDA for the inspection carried out at the Oncology (Injectable and Oral Solid) Formulation Facility (F-2) at Panelav.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.